167 related articles for article (PubMed ID: 25199719)
1. Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
Cozzarini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):e113-4. PubMed ID: 25199719
[No Abstract] [Full Text] [Related]
2. Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30.
De Bari B; Alongi F; Arcangeli S
Eur Urol; 2014 Dec; 66(6):e111-2. PubMed ID: 25190611
[No Abstract] [Full Text] [Related]
3. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2.
Fiorino C; Briganti A; Cozzarini C
Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947
[No Abstract] [Full Text] [Related]
4. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
5. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer.
Buyyounouski MK
Eur Urol; 2014 Dec; 66(6):1031-2. PubMed ID: 25130566
[No Abstract] [Full Text] [Related]
6. Reply to Berardino De Bari, Stefano Arcangeli, and Filippo Alongi's letter to the editor re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 2014;65:546-51.
Suardi N; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2015 Feb; 67(2):e27-8. PubMed ID: 25281387
[No Abstract] [Full Text] [Related]
7. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.
Mak RH; Hunt D; Efstathiou JA; Heney NM; Jones CU; Lukka HR; Bahary JP; Patel M; Balogh A; Nabid A; Leibenhaut MH; Hamstra DA; Roof KS; Jeffrey Lee R; Gore EM; Sandler HM; Shipley WU
Urol Oncol; 2016 Oct; 34(10):430.e1-7. PubMed ID: 27381895
[TBL] [Abstract][Full Text] [Related]
8. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
10. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients.
Cozzarini C; Fiorino C; Da Pozzo LF; Alongi F; Berardi G; Bolognesi A; Briganti A; Broggi S; Deli A; Guazzoni G; Perna L; Pasetti M; Salvadori G; Montorsi F; Rigatti P; Di Muzio N
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):191-9. PubMed ID: 21109361
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
12. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
13. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
[TBL] [Abstract][Full Text] [Related]
14. Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer.
Carillo V; Cozzarini C; Rancati T; Avuzzi B; Botti A; Borca VC; Cattari G; Civardi F; Esposti CD; Franco P; Girelli G; Maggio A; Muraglia A; Palombarini M; Pierelli A; Pignoli E; Vavassori V; Zeverino M; Valdagni R; Fiorino C
Radiother Oncol; 2014 Apr; 111(1):100-5. PubMed ID: 24631144
[TBL] [Abstract][Full Text] [Related]
15. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
[TBL] [Abstract][Full Text] [Related]
16. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
17. Urologic Complications Following Pelvic Radiotherapy.
Lobo N; Kulkarni M; Hughes S; Nair R; Khan MS; Thurairaja R
Urology; 2018 Dec; 122():1-9. PubMed ID: 30036617
[TBL] [Abstract][Full Text] [Related]
18. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's letter to the editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
Abdollah F; Briganti A
Eur Urol; 2013 Nov; 64(5):e103-4. PubMed ID: 23915876
[No Abstract] [Full Text] [Related]
19. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy.
Marks LB; Carroll PR; Dugan TC; Anscher MS
Int J Radiat Oncol Biol Phys; 1995 Mar; 31(5):1257-80. PubMed ID: 7713787
[TBL] [Abstract][Full Text] [Related]
20. Reply to Filippo Alongi, Rosario Mazzola, Dario Aiello and Matteo Salgarello's Letter to the Editor re: Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. A Step Forward in the Era of Functional Imaging?: Functional Imaging and Micrometastatic Disease: Implications for Radiotherapy Field Design.
Spratt DE; Zelefsky MJ
Eur Urol; 2017 Apr; 71(4):e123-e124. PubMed ID: 27836418
[No Abstract] [Full Text] [Related]
[Next] [New Search]
